Related Experiment Video

Updated: Aug 15, 2026

Isolation of Functional Cardiac Immune Cells
07:26

Isolation of Functional Cardiac Immune Cells

Published on: December 5, 2011

A glossary of circulating cytokines in chronic heart failure

S Adamopoulos1, J T Parissis, D T Kremastinos

  • 1Second Department of Cardiovascular Medicine, Onassis Cardiac Surgery Center, Zinonos 9, Halandri, 15234, Athens, Greece. elbee@ath.forthnet.gr

European Journal of Heart Failure
|October 12, 2001
PubMed

Insights

Cytokines, or signaling proteins, are key drivers in chronic heart failure development. This review details major cytokines, their regulation, and cardiovascular effects in heart failure.

Area of Science:

  • Cardiovascular Medicine
  • Immunology
  • Molecular Biology

Background:

  • Chronic heart failure (CHF) involves complex biological processes.
  • Biologically active molecules called cytokines play a crucial role in CHF.
  • Inflammatory factors are increasingly recognized in heart failure pathophysiology.

Purpose of the Study:

  • To provide a comprehensive glossary of major cytokines and related inflammatory factors in CHF.
  • To describe the synthesis and regulation of these factors.
  • To analyze their specific biologic effects on the cardiovascular system.

Main Methods:

  • Literature review and synthesis of existing research.
  • Compilation of data on cytokine sources and regulatory mechanisms.
  • Analysis of reported cardiovascular effects of cytokines.

Main Results:

  • Identification of key cytokines implicated in CHF.
  • Summary of factors influencing cytokine secretion.
  • Detailed description of cytokine actions on the cardiovascular system.

Conclusions:

  • Cytokines are central to the pathophysiology of chronic heart failure.
  • Understanding cytokine regulation and effects is vital for CHF research.
  • Targeting cytokine pathways may offer therapeutic strategies for heart failure.

More Related Videos

Multiplex Cytokine Profiling of Stimulated Mouse Splenocytes Using a Cytometric Bead-based Immunoassay Platform11:00

Multiplex Cytokine Profiling of Stimulated Mouse Splenocytes Using a Cytometric Bead-based Immunoassay Platform

Published on: November 9, 2017

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.